Quidelortho Corp
F:QL1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quidelortho Corp
Cash from Investing Activities
Quidelortho Corp
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidelortho Corp
F:QL1A
|
Cash from Investing Activities
-$192.7m
|
CAGR 3-Years
51%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-27%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Investing Activities
-$2.6B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-2%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Investing Activities
-$712.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-23%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Investing Activities
-$4.9B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Investing Activities
-$2.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Investing Activities
$665.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Quidelortho Corp
Glance View
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
See Also
What is Quidelortho Corp's Cash from Investing Activities?
Cash from Investing Activities
-192.7m
USD
Based on the financial report for Dec 28, 2025, Quidelortho Corp's Cash from Investing Activities amounts to -192.7m USD.
What is Quidelortho Corp's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-27%
Over the last year, the Cash from Investing Activities growth was -29%. The average annual Cash from Investing Activities growth rates for Quidelortho Corp have been 51% over the past three years , -25% over the past five years , and -27% over the past ten years .